A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment
• •History of prior significant toxicity from another phosphoinositide 3-kinase (PI3K) or Akt pathway or mammalian target of rapamycin (mTOR) inhibitor requiring discontinuation of treatment
• •Anti-cancer therapy within 28 days prior to first dose of study drug, except as stated in protocol
• •History of type I or type II diabetes mellitus requiring insulin
• •Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease)
• •Clinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B or hepatitis C virus
• •Active autoimmune disease
• •Pregnant or lactating women
• •Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
• •History of glaucoma
• •History of retinal vein occlusion